GenMark Diagnostics, Inc. (NASDAQ:GNMK) insider Hany Massarany sold 8,252 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $4.74, for a total transaction of $39,114.48. Following the completion of the transaction, the insider now directly owns 362,957 shares in the company, valued at $1,720,416.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Hany Massarany also recently made the following trade(s):

  • On Thursday, November 2nd, Hany Massarany sold 1,588 shares of GenMark Diagnostics stock. The shares were sold at an average price of $7.24, for a total transaction of $11,497.12.

GenMark Diagnostics, Inc. (NASDAQ GNMK) traded up $0.07 on Wednesday, hitting $4.71. 425,800 shares of the company were exchanged, compared to its average volume of 423,827. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.77 and a current ratio of 2.97. GenMark Diagnostics, Inc. has a one year low of $3.63 and a one year high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. The firm had revenue of $11.60 million for the quarter, compared to the consensus estimate of $14.56 million. During the same period in the previous year, the business earned ($0.27) earnings per share. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. equities research analysts predict that GenMark Diagnostics, Inc. will post -1.17 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/22/genmark-diagnostics-inc-gnmk-insider-hany-massarany-sells-8252-shares-of-stock.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its position in shares of GenMark Diagnostics by 2.1% during the second quarter. Legal & General Group Plc now owns 11,521 shares of the medical equipment provider’s stock valued at $137,000 after purchasing an additional 240 shares in the last quarter. Rhumbline Advisers lifted its position in shares of GenMark Diagnostics by 0.8% during the second quarter. Rhumbline Advisers now owns 48,445 shares of the medical equipment provider’s stock valued at $573,000 after purchasing an additional 408 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of GenMark Diagnostics by 0.8% during the second quarter. TIAA CREF Investment Management LLC now owns 168,888 shares of the medical equipment provider’s stock valued at $1,998,000 after purchasing an additional 1,268 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of GenMark Diagnostics by 4.1% during the second quarter. The Manufacturers Life Insurance Company now owns 36,023 shares of the medical equipment provider’s stock valued at $426,000 after purchasing an additional 1,410 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC lifted its position in shares of GenMark Diagnostics by 18.4% during the second quarter. Quantitative Systematic Strategies LLC now owns 13,147 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 2,047 shares in the last quarter.

A number of research analysts have weighed in on the stock. Bank of America Corporation assumed coverage on shares of GenMark Diagnostics in a research note on Monday, September 18th. They issued a “buy” rating and a $13.00 price objective on the stock. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price objective on shares of GenMark Diagnostics in a research note on Thursday, August 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of GenMark Diagnostics in a research note on Wednesday, October 4th. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price objective on shares of GenMark Diagnostics in a research note on Monday, October 30th. Finally, Raymond James Financial, Inc. reaffirmed a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $11.80.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.